freeimages.co.uk
The British pharmaceutical giant is among several potential suitors for the company. Amylin has already rejected a $3.5bn approach from Bristol Myers Squibb, a fellow US drugs company that is thought to have made a renewed offer.
Other names that have been linked to a possible deal include US drug maker Merck, and Sanofi, the French pharmaceuticals group that employs 1,800 people in Britain.
For Astra, which on Sunday declined to comment, the purchase would enable it to replace sales lost on existing drugs when patent protection expires. The company is facing a looming “patent cliff” caused by a gap in the company’s drug development pipeline.
Read more
Posts related to Telegraph: AstraZeneca bids $4bn for diabetes specialist Amylin
A new study adds further weight to the argument that people who use the diabetes drug Actos are at higher risk of developing bladder cancer. ...
Doctors in India are seeking restraint in the use of commonly used drug pioglitazone, better known by brand name Glizone and Pioz, after the studies ...
A recent article reveals a new idea for designing new drug candidates for Type 2 diabetes mellitus. Written by Ngoc Doan Trang Nguyen and Ly Thi ...
Snake venom has potential as diabetes cure, study finds. Most snake widely known for its dangerous bit, and its causes some deaths accidents. Now, the recent study ...
This booklet offers 61 home remedies that just might help you with your diabetes. These natural remedies offer multiple advantages: 1) they're inexpensive which is ...